Estrogen dose in oral contraceptives: FDA committee examines safety and utility of 50 mcg estrogen OCs.
D000367:Age Factors; D000569:Americas; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D003710:Demography; D019049:Developed Countries; D004194:Disease; D004347:Drug Interactions; D004467:Economics; D004617:Embolism; D005193:Family Planning Services; D006262:Health; D006287:Health Planning Guidelines; D008389:Marketing of Health Services; D009656:North America; D004364:Pharmaceutical Preparations; D011153:Population; D011154:Population Characteristics; D019064:Product Packaging; D011634:Public Health; D012449:Safety; D013812:Therapeutics; D013923:Thromboembolism; D014481:United States; D014652:Vascular Diseases
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D004364:Pharmaceutical Preparations
Age Factors; Americas; Contraception; Contraceptive Agents, Estrogen--administraction and dosage; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents--administraction and dosage; Contraceptive Methods; Demographic Factors; Developed Countries; Diseases; Drug Interactions; Drugs; Economic Factors; Embolism; Family Planning; Health; Marketing; North America; Northern America; Oral Contraceptives; Oral Contraceptives, Combined; Packaging; Population; Population Characteristics; Public Health; Recommendations; Safety; Thromboembolism; Treatment; United States; Vascular Diseases